Molina Healthcare (MOH) Stock Looks Expensive On Illinois Contract Win

Molina Healthcare's stock has rallied strongly in the short term, yet the longer three year return is still deeply negative and the broader valuation checks lean expensive. This raises the question of how much of the Illinois Medicaid contract win is already reflected in the current price.

• Over the past three years, Molina Healthcare shares have declined 29.2%, which suggests that the recent strength is working off a weak longer term base rather than building on steady gains.
• The newly secured Illinois Medicaid managed care contract can support investor confidence in Molina Healthcare's future enrollment and revenue. However, execution risk around serving roughly 3.1 million beneficiaries and managing margins on that contract may weigh on how much investors are willing to pay for the stock.
• With a valuation score of 2 out of 6, Molina Healthcare does not screen as a clear bargain on the broader set of valuation checks.

The issue now is whether the current share price leaves enough room for upside if the recent contract win and momentum are already largely priced into Molina Healthcare.

Find out why Molina Healthcare's 23.2% return over the last year is lagging behind its peers.

Is Molina Healthcare Getting Expensive on Earnings?

P/E is a useful check for Molina Healthcare because earnings are a key output of how well it prices and manages its Medicaid and other health plans. On this measure, the stock trades on about 62.4x earnings, which is meaningfully above the Healthcare industry average of 26.0x and also higher than the peer average of 32.8x.

The fair P/E multiple implied by the broader model is 45.3x. This indicates that Molina Healthcare is trading at a clear premium to what that framework suggests would be reasonable given its profile. Despite the recent Illinois Medicaid contract win lifting sentiment and the share price, the current valuation already assumes a lot of earnings strength relative to both sector norms and the tailored fair ratio.

On the P/E multiple, Molina Healthcare stock appears expensive compared with both industry benchmarks and the fair value yardstick.

See what the numbers say about this price — find out in our valuation breakdown.

The Molina Healthcare Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Molina Healthcare pick up where the valuation puzzle leaves off by spelling out what would need to happen to the company's growth, margins and earnings for the stock to be worth materially more or less than today. Each Narrative ties its number to a concrete view of how Molina Healthcare's growth, profitability and risks might evolve, giving you a clear reference point to revisit as fresh information comes through.

Community views on Molina Healthcare sit far apart, with one side arguing the stock still underprices its Medicaid engine and the other warning expectations have run ahead of earnings risk.

Bull case: 21% undervalued

"Molina's substantial investment in digital infrastructure and care management not only improves cost control, but also enhances member engagement and drives higher retention..."

Read the full Bull Case to see why Molina Healthcare could be undervalued

Bear case: 18% overvalued

"Potential Medicaid funding cuts or program changes could negatively impact Molina Healthcare's revenue and earnings trajectory..."

Read the full Bear Case to see why Molina Healthcare could be overvalued

Do you think there's more to the story for Molina Healthcare? Head over to our Community to see what others are saying!

The Bottom Line

For Molina Healthcare, the valuation work points to a stock that already prices in a generous earnings outlook, with market multiples indicating it screens as overvalued rather than obviously cheap. With no intrinsic value cross check in play, the case largely turns on whether the current premium P/E can be supported over time. The key question from here is whether Molina Healthcare can deliver the margin performance and contract execution, particularly in Illinois, that bulls believe justifies paying up, or whether expectations reset closer to sector norms.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com